302 | PREDICTING OUTCOMES IN DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS ELIGIBLE FOR FRONT‐LINE TRIALS USING HARKINS' ENHANCED ELIGIBILITY CRITERIA

Documenti analoghi

• Revisiting beta‐2 microglobulin as a prognostic marker in diffuse large B‐cell lymphoma
  di: Jelena Jelicic, et al.
  Pubblicazione: (2024)
• A Real‐World Data‐Based Analysis of Prognostic Indices as Part of Trial Eligibility Criteria in Diffuse Large B‐Cell Lymphoma Patients
  di: Jelena Jelicic, et al.
  Pubblicazione: (2024)
• Effectiveness of R‐CHOP versus R‐CHOEP for treatment of young patients with high‐risk diffuse large B‐cell lymphoma: A Danish observational population‐based study
  di: Rasmus Rask Kragh Jørgensen, et al.
  Pubblicazione: (2024)
• 664 | SIMPLIFIED MOLECULAR IPI AS ELIGIBILITY CRITERIA FOR CLINICAL TRIALS: ANALYSIS OF THE TURKISH LYMPHOMA STUDY GROUP’S LARGE B‐CELL LYMPHOMA COHORT
  di: U. Yılmaz, et al.
  Pubblicazione: (2025)
• Reducing the use of benzodiazepines and cyclopyrrolones in clinical practice
  di: Viggo Rask Kragh Jorgensen
  Pubblicazione: (2006)